Fresenius to fight adverse merger decision:
This article was originally published in Clinica
Fresenius (Germany) has vowed to challenge a decision taken this month by the cartel office barring its merger with Schiwa (see Clinica No 601, p 13). The court maintains that the merger would lead to a dominant position in the German infusion and dialysis products market. Fresenius, however, stresses the importance of strengthening its presence in the European market.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.